Nocturne Acquisition Corporation

Nocturne Acquisition Corporation

MBTC
Nocturne Acquisition CorporationUS flagNASDAQ Capital Market
11.66
USD
+0.46
- -
60.53MMarket Cap
Nocturne Acquisition Corporation
MBTC
(NASDAQ Capital Market)

Recent

price

11.66

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Nocturne Acquisition Corporation (NASDAQ:MBTC) is a blank check company formed as a Cayman Islands exempted company whose sole purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with no current significant operations or revenue generation. Incorporated on October 28, 2020, and headquartered in Wilmington, Delaware, with additional addresses referenced in Santa Ana, California, and La Jolla, California, the company targets opportunities particularly in disruptive technology sectors such as blockchain, artificial intelligence, and medical innovation; it maintains a lean structure led by CEO and Chairman Henry Monzon and CFO Ka Seng Ao. In a major recent development, the company pursued a reverse merger with Cognos Therapeutics Inc., a developer of implantable drug delivery systems like the SINNAIS smart pump for neurological treatments including brain cancer, filing a Form S-4 registration statement and engaging Chardan as advisor, but terminated the transaction in April 2024 due to inability to meet conditions, leading to public share redemption at approximately $11.79 per share, Nasdaq delisting via Form 25, and SEC registration termination via Form 15.

Company News

APIChat
  • Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing

  • Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos